Retatrutide vs Tirzepatide: Triple Agonist Against Dual Agonist

Retatrutide and tirzepatide are the two most discussed metabolic peptides of the current research era, and they are constantly pitted against each other in headlines that reduce a complex pharmacological question to a single number. This article does the opposite. It compares the triple agonist against the dual agonist at the level that actually matters: receptor mechanism, trial architecture, evidence maturity, and research utility. The single most important thing to understand up front is that the headline weight-loss figures come from different trials, at different durations, in different populations, and cannot be laid side by side as a fair contest. Most sites skip that caveat. We build the whole article around it.

Research-use framing only. Retatrutide (LY3437943) is an investigational compound developed by Eli Lilly and is NOT approved by the FDA for any use. Tirzepatide is FDA approved for type 2 diabetes and chronic weight management. Nothing here is medical advice or a protocol recommendation. All figures trace to the named clinical literature below.

The Core Distinction in One Sentence

Tirzepatide activates two receptors: GIP and GLP-1. Retatrutide activates three: GIP, GLP-1, and glucagon (GCGR). That single added receptor arm, the glucagon receptor, is the entire mechanistic differentiator between these two molecules, and every downstream difference in the data flows from it.

Receptor Mechanisms Side by Side

Both compounds are single synthetic molecules engineered to hit multiple incretin receptors at once. They are not blends of separate drugs. The engineering challenge is balancing potency across each receptor so that no single pathway dominates and produces off-target effects.

The GIP and GLP-1 arms are shared. GLP-1 drives glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and hypothalamic satiety. GIP adds adipocyte-level effects and appears to enhance GLP-1 satiety signaling. If retatrutide is understood as tirzepatide plus one more receptor, that is a useful first approximation, though the receptor balance and potencies are not identical.

What the Glucagon Receptor Arm Adds

This is the crux of the comparison, so it deserves its own section. Glucagon in isolation is hyperglycemic and historically viewed as a metabolically harmful hormone, since it raises hepatic glucose output. The apparent paradox is that adding glucagon receptor agonism produces greater weight loss without producing hyperglycemia. The resolution is co-activation: when the GLP-1 arm is firing simultaneously, insulin secretion offsets the glucose-raising signal, and what is left over are the beneficial glucagon effects.

Those beneficial effects are two, and they are exactly the things tirzepatide does less of:

• Increased energy expenditure. Glucagon receptor activation raises basal metabolic rate and promotes thermogenesis. This is a "burn more" mechanism that operates independently of appetite. Tirzepatide primarily reduces energy intake; retatrutide reduces intake AND raises expenditure. That is why the glucagon arm can push total weight loss past what appetite suppression alone achieves.
• Hepatic fat mobilization. Glucagon receptors in the liver drive fatty acid oxidation, directly mobilizing stored hepatic fat. This is why retatrutide's liver-fat data is so striking, and why the glucagon arm is the specific feature that makes retatrutide a compound of interest for MASLD and steatohepatitis research beyond generic weight loss.

That is the whole differentiator. Everything else in this comparison, higher weight-loss ceiling, dramatic liver-fat reduction, a distinct heart-rate signal, is a consequence of adding the glucagon receptor to a dual-agonist backbone.

Head to Head Efficacy: The Numbers, and Why You Cannot Compare Them Directly

Here are the two most-quoted figures placed side by side, along with the reason you should distrust anyone who lays them out this way without a warning label.

At a glance retatrutide "wins" by roughly three percentage points in less time. That comparison is misleading, and here is why, spelled out rather than hand-waved:

• Different trials, never randomized against each other. No head-to-head study of retatrutide versus tirzepatide has been published. Cross-trial comparison ignores differences in baseline weight, enrollment criteria, titration schedules, and site effects.
• Different durations. Retatrutide's -24.2% is at 48 weeks. Tirzepatide's -20.9% is at 72 weeks. Weight-loss curves with these compounds are still descending at 48 weeks and have not fully plateaued, so comparing a 48-week number to a 72-week number is not comparing like with like.
• Different sample sizes and precision. Retatrutide's figure comes from an arm of roughly 60 people in a 338-person Phase 2 trial. Tirzepatide's comes from a 2,539-person Phase 3 trial. The confidence intervals are not remotely the same width.
• Different evidence maturity. One number is a Phase 2 signal. The other is a Phase 3 result that has since been reinforced by an entire trial program.

Normalizing by Timepoint: The Comparison Most Sites Refuse to Make

The single most honest thing we can do is anchor on the same timepoint. Retatrutide reported an interim figure, and that lets us at least align the clocks, even if the populations still differ.

The takeaway from this table is not "retatrutide is better." It is that the two datasets barely overlap in time. Retatrutide's trial ended at 48 weeks; tirzepatide's primary obesity endpoint is at 72 weeks. The fair statement the literature supports is narrow: at 48 weeks, retatrutide's top dose produced a larger mean weight reduction than tirzepatide's top dose produced at 72 weeks in a separate trial. That is a hypothesis-generating observation, not a proof of superiority. You can run the dosing math yourself with the dose calculator, but no calculator can fix the fact that these are different studies.

Full Comparison Across Every Axis

Dosing and Pharmacokinetics

Both are once-weekly subcutaneous compounds, which is a direct consequence of their long half-lives. Retatrutide's terminal half-life is about 6 days with a Tmax of roughly 24 to 48 hours, which comfortably supports weekly dosing. Tirzepatide sits around 5 days. From a research-scheduling standpoint the two are functionally interchangeable in cadence: one injection per week, steady-state reached after several weeks of consistent dosing.

Side Effect Profiles

Both compounds share the incretin-class gastrointestinal signature: nausea, vomiting, diarrhea, and constipation, all dose dependent, mostly mild to moderate, and worst during dose escalation. For retatrutide the Phase 2 data documented discontinuation due to adverse events in roughly 6 to 16% across dose arms. The distinctive retatrutide finding is a dose-dependent heart-rate increase that peaked around 24 weeks and then declined, a signal attributable to the glucagon arm and not typically emphasized for tirzepatide. For a full breakdown see the retatrutide side effects guide.

Liver Fat: Where the Glucagon Arm Shows Off

Both compounds reduce liver fat, but retatrutide's numbers are in a different category because of the glucagon mechanism. In a 2023 liver-fat substudy, participants with MASLD saw liver fat content reduced by up to about 86% at 24 weeks, with roughly 80% reaching normal liver fat content (under 5%). Tirzepatide has documented liver-fat and steatohepatitis benefit in its own dedicated trial, but the glucagon-driven hepatic fatty acid oxidation is the specific reason retatrutide's liver signal is so large. If a research objective centers on hepatic fat, this is the most decision-relevant difference between the two.

Cost, Availability, and Legal Status

This is not a close call and it is the most practically important axis. Tirzepatide is an approved medication with a legitimate supply chain. Retatrutide has no approved supply and exists in the research space only through the grey market, where it is frequently marketed under the nicknames "GLP-3" or "triple G." Those terms are marketing shorthand, not pharmacology. There is no such thing as a GLP-3 receptor. Retatrutide is a GIP/GLP-1/glucagon triple agonist, and any vendor using "GLP-3" is signaling marketing spin rather than mechanistic accuracy. Vet any source carefully using the vendor directory and read where to buy retatrutide in 2026 before assuming any grey-market material is what it claims to be.

Why Cross-Trial Comparison Is Misleading: A Rigorous Look

It is worth being explicit about the statistical traps, because the retatrutide-versus-tirzepatide "debate" is built almost entirely on committing them.

• Ceiling not reached. Retatrutide's 48-week curve had not plateaued. Extrapolating that a 72-week retatrutide number would beat tirzepatide's 72-week number is speculation, not data. The honest position is that we do not have a 72-week retatrutide obesity figure.
• Responder distribution matters more than the mean. Means hide the shape of the response. In the retatrutide Phase 2 obesity trial, 100% of the 8 mg and 12 mg arms reached at least 5% weight loss at 48 weeks, and roughly 26% of the 12 mg arm reached at least 30% weight loss. A single mean does not capture that the top dose pushed a meaningful minority into very high loss territory.
• Phase 2 signals shrink. It is common for Phase 2 effect sizes to attenuate in larger Phase 3 populations. Tirzepatide's number is already the Phase 3 number. Retatrutide's is not, so they are not the same kind of evidence.
• No shared control. The two trials had different placebo arms (retatrutide placebo was -2.1% at 48 weeks; SURMOUNT-1 placebo was different), so even placebo-adjusted deltas are not perfectly comparable.

The intellectually honest summary: retatrutide's Phase 2 signal is genuinely impressive and plausibly points toward a higher ceiling, driven by the added glucagon mechanism, but "plausibly points toward" is the correct strength of claim. Anyone stating flatly that retatrutide beats tirzepatide is overreading the data. For the three-way version of this analysis including semaglutide, see the retatrutide vs tirzepatide vs semaglutide comparison.

Decision Matrix: Which Compound Suits Which Research Objective

Different research questions favor different compounds. This matrix maps objective to the better-suited molecule, on the current evidence.

The one-line rule of thumb: tirzepatide is the mature, well-characterized choice, and retatrutide is the higher-ceiling, higher-uncertainty frontier choice whose distinctive value is the glucagon arm's liver and energy-expenditure effects. Take the quiz or log observations in the tracker if you want to structure your own read of the two, and use the learn hub for the underlying incretin biology.

Evidence Maturity: The Asymmetry That Should Anchor Every Comparison

If you remember one thing, make it this. Tirzepatide has a complete Phase 3 program spanning obesity, type 2 diabetes, sleep apnea, heart failure, and steatohepatitis, plus years of real-world use. Retatrutide has one Phase 2 obesity trial (n=338), one Phase 2 type 2 diabetes trial (n=281, HbA1c reduction up to -2.02% at 12 mg versus -0.01% placebo and -1.41% for dulaglutide 1.5 mg), and a liver-fat substudy. Its Phase 3 program, TRIUMPH (TRIUMPH-1 through TRIUMPH-4 plus a cardiovascular outcomes study), is ongoing and has not read out. Comparing a Phase 3 body of evidence to a Phase 2 signal is the fundamental asymmetry, and it should temper every "retatrutide beats tirzepatide" headline you encounter. For the deeper primary-literature walkthrough, see what the retatrutide studies show.

Frequently Asked Questions

Is retatrutide better than tirzepatide?

On the current data you cannot make that claim rigorously. Retatrutide's top-dose Phase 2 figure (-24.2% at 48 weeks) is higher than tirzepatide's top-dose Phase 3 figure (-20.9% at 72 weeks), but these are different trials at different durations in different populations, with no head-to-head study. Retatrutide's signal is promising but immature.

What does the glucagon receptor actually add over tirzepatide?

Two things tirzepatide does less of: increased energy expenditure (the glucagon arm raises metabolic rate independently of appetite) and hepatic fat mobilization (glucagon receptors in the liver drive fatty acid oxidation). Together these are the entire mechanistic differentiator between the triple and dual agonists.

Why is retatrutide called GLP-3 or triple G?

Those are grey-market marketing nicknames, not real pharmacology. Retatrutide is a GIP, GLP-1, and glucagon triple receptor agonist. There is no GLP-3 receptor. Treat any vendor leaning on the "GLP-3" label as using marketing spin rather than accurate mechanism.

Do they have similar side effects?

Both share the incretin-class gastrointestinal profile: nausea, vomiting, diarrhea, and constipation, dose dependent and worst during escalation. The retatrutide-specific finding is a dose-dependent heart-rate increase peaking around 24 weeks then declining, attributed to the glucagon arm.

Which has better liver fat data?

Retatrutide, on the strength of its glucagon mechanism. A 2023 substudy reported liver fat reduced by up to about 86% at 24 weeks in MASLD participants, with about 80% reaching normal liver fat (under 5%). Tirzepatide also reduces liver fat and has a dedicated steatohepatitis trial, but retatrutide's signal is larger.

Can I buy retatrutide the way I can get tirzepatide?

No. Tirzepatide is FDA approved with a legitimate pharmacy supply chain. Retatrutide is investigational, has no approved supply, and circulates only through the grey market. That difference in availability and quality assurance is one of the most practically important distinctions between the two.

Will retatrutide's Phase 2 lead hold up in Phase 3?

Unknown. Phase 2 effect sizes commonly attenuate in larger Phase 3 populations, and the ongoing TRIUMPH program has not read out. The honest expectation is that we will not know how retatrutide truly compares until those results and, ideally, a head-to-head trial exist.

Key Research Citations